As Per the Report, the Size of the Perfusion Systems Market in the Middle East & Africa is valued at USD 0.09 billion in 2023 and is predicted to grow at a CAGR of 1.43%, to reach USD 0.1 billion by 2028 during the forecast period 2023 to 2028.
Factors driving growth in the perfusion systems market include the rising prevalence of cardiovascular and respiratory diseases, increased government and non-governmental initiatives to encourage organ donation, increased investment in cell-based research, rising biologics manufacturing activities, and government and NGO programs to promote organ donation.
In addition, introducing technologically improved products to improve efficiency and cost-effectiveness is projected to provide profitable prospects for this market. For example, portable organ perfusion systems are expected to gain popularity in the next few years due to associated benefits such as ease of access, cost-efficiency, and portability.
The devices are used in heart surgeries where perfusion experts use artificial blood pumps to push blood through patients' veins, effectively replacing the heart's function while the cardiac surgeon works. Perfusion systems are also employed in treating melanoma in the arms and legs with chemotherapy. In addition, the flow of blood to the limb is temporarily interrupted with this approach, and anticancer medications are injected directly into the limb's circulation.
Other reasons, such as expanding pharmaceutical research in this region and a growing inclination for continuous research, are expected to contribute to the MEA perfusion system market's expansion. In recent years, the number of heart and pancreatic transplants has broadened the market for perfusion systems. In addition, clinicians are testing novel technologies in the perfusion systems market due to advancements in vascularized composite all transplantation.
Over the last few decades, significant progress has been achieved in improving transplantation outcomes for various solid organ transplants. In addition, the emerging 3D framework has enhanced the clinical potential of novel perfusion systems.
During the forecast period, however, the high cost of organ transplantation, ethical concerns about stem cell research activities, & the high cost of cell-based research are projected to hinder the market's expansion.
This research report on the Middle East & Africa Perfusion Systems Market has been segmented and sub-segmented into the following categories.
Geographically, the MEA Perfusion Systems Market holds the smallest market share globally. As a result of US sanctions, Iran's economy was in terminal decline. The primary sources of economic stability in Middle Eastern countries are oil production and export. On the other hand, the newest pandemic is wreaking havoc on the Middle East's economy.
The UAE perfusion systems market is projected to witness a significant CAGR because the region has seen a sharp decline in local and external demand for goods and products and production halts owing to workforce shortages.
The Saudi Arabia perfusion systems market is predicted to grow significantly due to the spread of coronavirus in the area, putting a lot of strain on healthcare workers. Emergency cardiac procedures, coronavirus patient treatment, and the implementation of safety standards to prevent virus spread impose pressure on cardiac surgeons. In addition, elective operations and organ transplantation procedures were harmed due to the virus's rapid spread. The market for medical perfusion technology in the Middle East and Africa is expected to be hampered by these issues.
KEY MARKET PLAYERS
Key Market Companies leading the Middle East & Africa Perfusion Systems Market Profiled in the Report are Getinge AB, Medtronic plc, Terumo Corporation, XENIOS AG, Repligen Corporation, Spectrum Laboratories, Inc, ALA Scientific Instruments, Inc., LivaNova PLC, Merck KGaA, Harvard Bioscience, Inc.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org